HempNewsBreaks – InMed Pharmaceuticals (IMLFF) Announces Filing of Provisional Patent for INM-085

Pre-clinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (OTCQB: IMLFF) (CSE: IN) this morning announced the filing of a provisional patent application in the United States for INM-085 as a cannabinoid-based topical therapy for glaucoma. The company notes that this move marks an important step toward providing intellectual and commercial protection for INM-085. If approved, INM-085 could address an expansive global market that’s currently valued in excess of $5 billion. Per this morning’s update, glaucoma is currently the second-leading cause of blindness, driven by risk factors such as increased pressure in the eye, a family history of the condition, migraines, high blood pressure and obesity. With INM-085, InMed is seeking to reduce intraocular pressure associated with glaucoma through a single daily eye drop administered immediately prior to the patient’s bedtime. The company also intends to initiate discussions with potential partners regarding its proprietary delivery system for ophthalmic drugs, which it anticipates could play a key role in reducing the high rates of non-adherence that are often present with currently-approved glaucoma therapies.

To view the full press release, visit http://nnw.fm/3oYRA

About InMed

InMed is a pre-clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed’s proprietary bioinformatics database drug/disease targeting tool, cannabinoid biosynthesis technology and drug development pipeline are the fundamental value drivers of the Company. For more information, visit www.inmedpharma.com

About NetworkNewsBreak

NetworkNewsBreak (NNB) provides a rapid summary of corporate news that caught the attention of HempWire (HW). NNB keeps you up-to-date on active US Public Companies complementary to HW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, HW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. HW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, HW brings its clients unparalleled visibility, recognition and brand awareness. HW is where news, content and information converge.

Please see full disclaimers on the HempWire website applicable to all content provided by HW, wherever published or re-published: https://www.hempwire.com/disclaimer/

HempWire (HW)
Denver, CO
www.hempwire.com
303.498.7722 Office
Editor@HempWire.net